Richter A, Löscher W
Department of Pharmacology, Toxicology, and Pharmacy, School of Veterinary Medicine, Hannover, Germany.
Pharmacol Biochem Behav. 1995 Dec;52(4):655-65. doi: 10.1016/0091-3057(95)00162-p.
The genetically dystonic (dtsz) hamster is an autosomal recessive mutant that shares several features with paroxysmal dystonia, i.e., a subcategory of inherited idiopathic dystonia in humans. Because the serotonin (5-HT) system has been suggested to be involved in dystonia, we examined the functional responsiveness of the 5-HT system in dystonic hamsters by administering various 5-HT agonists and antagonists selective for different receptor subtypes and observing the effects on dystonic attacks as well as the behavioural responses associated with drug administration. Paradoxically, marked prodystonic effects (i.e., increased severity and/or decreased latency of dystonic attacks) were seen with both the selective 5-HT1A receptor agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) and the selective and "silent" 5-HT1A receptor antagonist, N-tert-butyl-3[4-(2-methoxyphenyl)piperazin-1-yl]-2- phenylpropionamide [(+)-WAY-100135], whereas other 5-HT1A receptor antagonists, i.e., methyl 4[4-(4-[1,1,3-trioxo-2H-1,2-benzoiosothiazol-2-yl]butyl)-1- piperazinyl]1-H-indole-2-carboxylate (SDZ 216-525) and N1-bromoacetyl-N8-3'-(4-indolyloxy)-2'-hydroxypropyl-(Z)-1,8- diamino-p-methane (pindobind-5-HT1A) did not alter dystonia to any comparable extent. Because among these 5-HT1A receptor antagonists, (+)-WAY-100135 is the only drug known to be not only silent at postsynaptic but also presynaptic (somatodendritic) 5-HT1A receptors, the marked prodystonic effect of this drug could relate to increased 5-HT release as a result of the blockade of somatodendritic 5-HT1A receptors. The only 5-HT1A receptor antagonist that exerted antidystonic effects in hamsters was pindolol, which, however, could be related to its beta-adrenoceptor blocking action. The 5-HT1A receptor partial agonist ipsapirone exerted moderate prodystonic activity. Prodystonic activity was also determined for the mixed 5-HT1A/5-HT2 receptor agonist 5-methoxy-N,N-dimethyltryptamine, although this drug was less potent in this regard than 8-OH-DPAT. The 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerted prodystonic effects in mutant hamsters, which, however, were also seen after the administration of the 5-HT2 receptor antagonist ritanserin. Collectively, the results of this study demonstrate that dystonia in genetically dystonic hamsters can be affected by pharmacologic manipulation of 5-HT receptors. The data may also indicate that dystonia is not a potential clinical application for selective 5-HT1A or 5-HT2 receptor antagonists.
遗传性肌张力障碍(dtsz)仓鼠是一种常染色体隐性突变体,具有与阵发性肌张力障碍相同的一些特征,阵发性肌张力障碍是人类遗传性特发性肌张力障碍的一个子类。由于血清素(5-HT)系统被认为与肌张力障碍有关,我们通过给予对不同受体亚型具有选择性的各种5-HT激动剂和拮抗剂,并观察其对肌张力障碍发作以及与药物给药相关的行为反应的影响,来检测肌张力障碍仓鼠中5-HT系统的功能反应性。矛盾的是,选择性5-HT1A受体激动剂8-羟基-2(二正丙基氨基)四氢萘(8-OH-DPAT)和选择性“沉默”5-HT1A受体拮抗剂N-叔丁基-3[4-(2-甲氧基苯基)哌嗪-1-基]-2-苯基丙酰胺[(+)-WAY-100135]均出现了明显的促肌张力障碍作用(即肌张力障碍发作的严重程度增加和/或潜伏期缩短),而其他5-HT1A受体拮抗剂,即4-[4-(4-[1,1,3-三氧代-2H-1,2-苯并异噻唑-2-基]丁基)-1-哌嗪基]-1-H-吲哚-2-羧酸甲酯(SDZ 216-525)和N1-溴乙酰基-N8-3'-(4-吲哚氧基)-2'-羟基丙基-(Z)-1,8-二氨基对甲苯(pindobind-5-HT1A)在任何可比程度上均未改变肌张力障碍。因为在这些5-HT1A受体拮抗剂中,(+)-WAY-100135是唯一已知不仅对突触后而且对突触前(体树突)5-HT1A受体无作用的药物,该药物明显的促肌张力障碍作用可能与体树突5-HT1A受体被阻断导致5-HT释放增加有关。在仓鼠中发挥抗肌张力障碍作用的唯一5-HT1A受体拮抗剂是吲哚洛尔,然而,这可能与其β-肾上腺素能受体阻断作用有关。5-HT1A受体部分激动剂伊沙匹隆具有中度促肌张力障碍活性。对于5-HT1A/5-HT2受体混合激动剂5-甲氧基-N,N-二甲基色胺也测定了其促肌张力障碍活性,不过该药物在这方面的效力低于八氢吡啶并吲哚。5-HT2受体激动剂1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)在突变仓鼠中发挥了促肌张力障碍作用,然而,在给予5-HT2受体拮抗剂利坦色林后也观察到了这种作用。总体而言,本研究结果表明,遗传性肌张力障碍仓鼠的肌张力障碍可受5-HT受体的药理调控影响。这些数据还可能表明,选择性5-HT1A或5-HT2受体拮抗剂在肌张力障碍方面并无潜在临床应用价值。